The use of recombinant activated factor VII in the circumcision operation in the case of a congenital factor VII deficiency

Canatan D, Eren E, Ozgüner IF, Duman H, Eren C, Büyükyavuz I, Savaş C.Blood Coagul Fibrinolysis. 2007 Jun;18(4):375-6. doi: 10.1097/MBC.0b013e3280c60d13.

Abstract

Congenital factor VII deficiency is a rare autosomal recessive hemorrhagic disorder and surgery is normally the cause of excessive bleeding. In this report, we describe the first case with congenital factor VII deficiency admitted to our clinics for the sunnet operation (circumcision), in which recombinant activated factor VII (rFVIIa; NovoSeven) was used to manage the bleeding. The patient was an 8-year old boy with moderate factor VII deficiency (factor VII level, 4%), and rFVIIa was administered at a dose of 20 microg/kg per dose during the circumcision operation. The same dose was repeated at 2, 4, 6, 9, 12, 15, 18, 21 and 24 h post operation. The circumcision operation could therefore be safely performed in patients with congenital factor VII using rFVIIa.

Share with

Prof. Dr. Behçet İlker BÜYÜKYAVUZ

Prof. Dr. Behçet İlker BÜYÜKYAVUZ, after his medical education at Atatürk University, he conducted research in the fields of genetics and pancreatic surgery at Ohio State University in Columbus, USA. After his specialization training at Hacettepe University Department of Pediatric Surgery, he started his academic career at Isparta Süleyman Demirel University. He retired in 2023 from the university where he worked as a Professor Doctor since 2012.

Leave a Comment

Your email address will not be published. Required fields are marked *